Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Radiation Fibrosis Syndrome 2Pancreatic Neoplasms 2Pancreatic Adenocarcinoma 2Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Pancreatic Ductal Adenocarcinoma 1Osteosarcoma 1Neuroma, Acoustic 1Inflammation 1Fibrosis 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1Camurati-Engelmann Syndrome 1

Interventions

Paclitaxel 15Carboplatin 9liposomal doxorubicin 8Bevacizumab 8pembrolizumab 7Topotecan 6olaparib 4mirvetuximab soravtansine 4Nivolumab 4Cyclophosphamide 4niraparib 3fludarabine 3Gemcitabine 3Drug Therapy 3rucaparib 2ribociclib 2pegfilgrastim 2palbociclib 2oregovomab 2fludarabine phosphate 2Irinotecan 2Hyperthermic Intraperitoneal Chemotherapy 2Fulvestrant 2Cisplatin 2Blood Specimen Collection 21-dodecylpyridoxal 2trastuzumab deruxtecan 1sacituzumab govitecan 1isoquercitrin 1irinotecan sucrosofate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Ovarian Epithelial × Losartan × 1 year × Clear all
NCT07265739 2026-05-06

Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer

Massachusetts General Hospital

Phase 2 Not yet recruiting
27 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡